HAIKOU CITY, China, April 14, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. CPHI ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it is re-issuing its previous release that was made on March 31, 2020 to incorporate certain disclosures that are required under the NYSE American Company Guide Sections 401(h) and 610(b). Included below are these additional disclosures along with the previously disclosed financial results for the fiscal year ended December 31, 2019.
Full Year Highlights
- Revenue decreased 11.4% to $11.0 million in fiscal year 2019 from $12.3 million in fiscal year 2018;
- Gross margin was 13.6% in fiscal year 2019, compared to 16.0% in fiscal year 2018.
- Impairment loss was $17.0 million in fiscal year 2019 compared to $6.5 million in fiscal year 2018, which represented an increase of $10.5 million;
- Loss from operations was $20.4 million in fiscal year 2019 compared to $10.4 million in fiscal year 2018, which represented an increase of $10.0 million;
- Net loss was $20.7 million in fiscal year 2019 compared to $10.8 million in fiscal year 2018. Loss per common share was $0.48 per basic and diluted share in fiscal year 2019 compared with $0.25 per basic and diluted share in fiscal year 2018.
Ms. Zhilin Li, China Pharma's Chairman and CEO, commented, "In 2019, we were continuously influenced by the policies and market environment of the pharmaceutical industry in China. In particular, the various cost control related policies in connection with the healthcare insurance, Group Purchasing Organization ("GPO", a new drug purchasing practice in which the anticipated purchase volume will be announced in the tender announcement, and the suppliers will need to consider their manufacturing capacity in addition to the price) activities, consistency evaluation, and control of the percentage of drug expenditure among the total hospital expenditure. After evaluating the detailed rules of those major policies and considering the potential return of investment and our recent cash flow position, we have made the decision to impair all advances for our remaining four pipeline products in 2019. However, we may resume the development of these formulas in the future if sufficient funding and other favorable conditions arise." Ms. Li continued, "Nevertheless, we continue to explore in the field of comprehensive healthcare. Comprehensive healthcare focuses on people's daily life, aging and disease and pays attention to all kinds of risk factors and misunderstandings affecting health. We launched a wash-free sanitizer in early 2020 to address the market needs caused by COVID-19 in China. We aim to leverage our expertise in the PRC for the development, manufacture and commercialization of pharmaceutical and comprehensive healthcare products for the benefit of human health."
Full Year Results
Revenue decreased by 11.4% to $11.0 million for the year ended December 31, 2019, as compared to $12.3 million for the year ended December 31, 2018. This decrease in sales revenue was mainly due to the increased standards of drug tender procurement of GPO (drugs have to pass the consistency evaluation in order to participate in the GPO), and the decreased "drug ratio"(the ratio of drug expenditure to patients' total hospital expenditure) from 60% a few years ago to approximately 30% in 2019, which were promoted by the healthcare insurance cost control policy.
Gross profit for the year ended December 31, 2019 was $1.5 million, compared to $2.0 million in 2018. Our gross profit margin in 2019 was 13.6% compared to 16.0% in 2018. This decline in our gross profit margin was mainly due to a decrease in our sales but our fixed costs remained the same.
Our selling expenses for the year ended December 31, 2019 were $2.4 million, a decrease of $0.9 million compared to $3.2 million for the year ended December 31, 2018. Selling expenses accounted for 21.5% of the total revenue in 2019 compared to 26.1% in 2018.
Our general and administrative expenses for the year ended December 31, 2019 were $2.3 million, as compared to $1.9 million in 2018. General and administrative expenses accounted for 21.0% and 15.8% of our total revenues in 2019 and 2018, respectively.
Our bad debt expenses for the year ended December 31, 2019 was $0.003 million, which represented a decrease of $0.601 million compared to $0.604 million in 2018. The decrease in our bad debt expenses was mainly due to the Company's adjustment of its credit policies to customers and the request of more advanced payment from customers prior to the shipping of products for the year ended December 31, 2019 compared to December 31, 2018.
We recognized $17.02 million impairment loss for the year ended December 31, 2019, compared to $6.48 million in 2018, among which, there was an impairment loss for the advances made to laboratories for the years ended December 31, 2019 and 2018 in the amount of $17,015,117 and $6,134,271, respectively. As a pharmaceutical company, we have been focusing on the development and maintenance of our intangible assets, mainly in the form of medical formulas. The consistency evaluation is expected to have a significant impact on all generic products not only in our pipeline, but also throughout the existing Chinese market. After evaluating the detailed rules under this policy and considering the return of investment and our recent cash flow position, our management made certain assessments regarding the impairment of our intangible assets, and identified four and two formulas that were unlikely to generate positive cash flow in the foreseeable future and therefore recognized impairment loss on them accordingly as of December 31, 2019 and December 31, 2018, respectively. The management determined to impair all advances at December 31, 2019, but may resume the development of these formulas in the future if sufficient funding and other favorable conditions arise.
Net loss for year ended December 31, 2019 was $20.7 million, or $0.48 each basic and diluted share, compared to net loss of $10.8 million, or net loss of $0.25 each basic and diluted share, for the year ended December 31, 2018. The increase in net loss was mainly a result of the decrease in impairment of long term assets.
Financial Condition
As of December 31, 2019 the Company had cash and cash equivalents of $1.1 million compared to $1.2 million as of December 31, 2018. Consider using "Working capital deficit increased to $4.5 million as of December 31, 2019 from $1.3 million as of December 31, 2018.
As of December 31, 2019, our net accounts receivable was $0.6 million, compared to $0.9 million as of December 31, 2018.
For the year ended December 31, 2019, cash flow from operating activities was $0.6 million, as compared to $1.9 million in 2018.
Receipt of Audit Opinion with Going Concern Explanatory Paragraph
The audit opinion provided by the Company's independent registered public accounting firm relating to the Company's audited consolidated financial statements (the "financial statements") for the year ended December 31, 2019 included a going concern explanatory paragraph. The financial statements were included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on March 30, 2020. The explanatory paragraph in the opinion of the Company's independent registered public accounting firm notes that as discussed in Note 1 to the financial statements, the Company incurred recurring losses from operations, has net current liabilities and an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1 to the financial statements and the financial statements do not include any adjustments that might result from the outcome of this uncertainty.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.
- FINANCIAL TABLES FOLLOW –
CHINA PHARMA HOLDINGS, INC. | ||||
CONSOLIDATED BALANCE SHEETS | ||||
December 31, | December 31, | |||
2019 | 2018 | |||
ASSETS | ||||
Current Assets: | ||||
Cash and cash equivalents | $ 1,074,979 | $ 1,186,587 | ||
Restricted cash | 109,908 | 1,273,940 | ||
Banker's acceptances | 45,756 | 20,579 | ||
Trade accounts receivable, less allowance for doubtful | ||||
accounts of $17,575,100 and $17,815,075, respectively | 635,371 | 916,931 | ||
Other receivables, less allowance for doubtful | ||||
accounts of $22,729 and $34,884, respectively | 46,643 | 170,098 | ||
Advances to suppliers | 404 | 47 | ||
Inventory | 3,588,824 | 5,054,975 | ||
Prepaid expenses | 77,120 | 123,759 | ||
Total Current Assets | 5,579,005 | 8,746,916 | ||
Advances for purchases of intangible assets | - | 17,069,587 | ||
Property, plant and equipment, net | 16,313,827 | 19,294,379 | ||
Operating lease right of use asset | 136,779 | - | ||
Intangible assets, net | 205,611 | 266,443 | ||
TOTAL ASSETS | $ 22,235,222 | $ 45,377,325 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
Current Liabilities: | ||||
Trade accounts payable | $ 1,366,330 | $ 1,060,934 | ||
Accrued expenses | 189,880 | 310,804 | ||
Other payables | 3,560,332 | 3,065,508 | ||
Advances from customers | 505,398 | 525,647 | ||
Other payables - related parties | 2,071,986 | 1,633,263 | ||
Operating lease liability, current portion | 91,306 | - | ||
Current portion of construction loan facility | 2,150,168 | 2,181,360 | ||
Bankers' acceptance notes payable | 109,908 | 1,273,940 | ||
Total Current Liabilities | 10,045,308 | 10,051,456 | ||
Non-current Liabilities: | ||||
Construction loan facility | 2,150,168 | 4,362,720 | ||
Operating lease liability, net of current portion | 48,701 | - | ||
Deferred tax liability | 753,444 | 764,374 | ||
Total Liabilities | 12,997,621 | 15,178,550 | ||
Commitments and Contingencies (Note 9) | ||||
Stockholders' Equity: | ||||
Preferred stock, $0.001 par value; 5,000,000 shares authorized; | ||||
no shares issued or outstanding | - | - | ||
Common stock, $0.001 par value; 95,000,000 shares authorized; | ||||
43,579,557 shares and 43,579,557 shares outstanding, respectively | 43,580 | 43,580 | ||
Additional paid-in capital | 23,590,204 | 23,590,204 | ||
Retained (deficit) earnings | (25,972,402) | (5,270,358) | ||
Accumulated other comprehensive income | 11,576,219 | 11,835,349 | ||
Total Stockholders' Equity | 9,237,601 | 30,198,775 | ||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 22,235,222 | $ 45,377,325 | ||
- | - | |||
CHINA PHARMA HOLDINGS, INC. | |||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||
AND COMPREHENSIVE INCOME (LOSS) | |||||
For the Years | |||||
Ended December 31, | |||||
2019 | 2018 | ||||
Revenue | $ 10,923,936 | $ 12,330,687 | |||
Cost of revenue | 9,441,752 | 10,355,839 | |||
Gross profit | 1,482,184 | 1,974,848 | |||
Operating expenses: | |||||
Selling expenses | 2,352,610 | 3,216,512 | |||
General and administrative expenses | 2,289,520 | 1,949,921 | |||
Research and development expenses | 229,637 | 172,384 | |||
Bad debt expense | 3,153 | 604,388 | |||
Impairment loss | 17,015,117 | 6,479,057 | |||
Total operating expenses | 21,890,037 | 12,422,262 | |||
Loss from operations | (20,407,853) | (10,447,414) | |||
Other income (expense): | |||||
Interest income | 27,527 | 38,516 | |||
Interest expense | (321,718) | (451,258) | |||
Net other expense | (294,191) | (412,742) | |||
Loss before income taxes | (20,702,044) | (10,860,156) | |||
Income tax benefit | - | 109,989 | |||
Net loss | (20,702,044) | (10,750,167) | |||
Other comprehensive income - foreign currency | |||||
translation adjustment | (259,130) | (2,122,360) | |||
Comprehensive income (loss) | $ (20,961,174) | $ (12,872,527) | |||
Loss per share: | |||||
Basic and diluted | $ (0.48) | $ (0.25) | |||
Weighted average shares outstanding | 43,579,557 | 43,579,557 | |||
CHINA PHARMA HOLDINGS, INC. | ||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||
For the Years | ||||
Ended December 31, | ||||
2019 | 2018 | |||
Cash Flows from Operating Activities: | ||||
Net loss | $ (20,702,044) | $ (10,750,167) | ||
Depreciation and amortization | 2,928,799 | 3,258,739 | ||
Inventory write off | 253,465 | 954,311 | ||
Bad debt expense | 3,153 | 604,388 | ||
Deferred income taxes | - | 68,419 | ||
Impairment loss | 17,015,117 | 6,479,057 | ||
Changes in assets and liabilities: | ||||
Trade accounts and other receivables | (478,918) | 99,400 | ||
Advances to suppliers | (361) | (449,101) | ||
Inventory | 1,999,978 | 688,852 | ||
Trade accounts payable | 324,180 | (16,441) | ||
Accrued taxes payable | 12,971 | (147,099) | ||
Other payables and accrued expenses | 378,200 | 437,901 | ||
Change in bankers' acceptance notes payable | (1,158,728) | 625,128 | ||
Advances from customers | (12,875) | (25,127) | ||
Prepaid expenses | 45,375 | 53,860 | ||
Net Cash Provided by Operating Activities | 608,312 | 1,882,120 | ||
Cash Flows from Investing Activities: | ||||
Purchases of property and equipment | (136,003) | (51,145) | ||
Net Cash Used in Investing Activities | (136,003) | (51,145) | ||
Cash Flows from Financing Activities: | ||||
Payments of construction term loan | (2,174,399) | (2,263,877) | ||
Advances from related party | 691,459 | 287,423 | ||
Repayments to related party | (245,830) | - | ||
Net Cash Used in Financing Activities | (1,728,770) | (1,976,454) | ||
Effect of Exchange Rate Changes on Cash | (19,179) | (134,004) | ||
Net Decrease in Cash, Cash Equivalents and Restricted Cash | (1,275,640) | (279,483) | ||
Cash and Cash Equivalents at Beginning of Period | 2,460,527 | 2,740,010 | ||
Cash, Cash Equivalents and Restricted Cash at End of Period | $ 1,184,887 | $ 2,460,527 | ||
Cash and Cash Equivalents | 1,074,979 | 1,186,587 | ||
Restricted cash | 109,908 | 1,273,940 | ||
Cash, Cash Equivalents and Restricted Cash at End of Period | 1,184,887 | 2,460,527 | ||
Supplemental Cash Flow Information: | ||||
Cash paid for income taxes | $ - | $ - | ||
Cash paid for interest | $ 299,164 | $ 588,191 | ||
Supplemental Noncash Investing and Financing Activities: | ||||
Accounts receivable collected with banker's acceptances | 869,625 | 579,896 | ||
Inventory purchased with banker's acceptances | 843,867 | 597,686 | ||
Right-of-use assets obtained in exchange for operating lease obligations | 229,644 | - | ||
- | ||||
View original content:http://www.prnewswire.com/news-releases/updates---china-pharma-holdings-inc-reports-fiscal-year-2019-financial-results-301039882.html
SOURCE China Pharma Holdings, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
